Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Christy Arrowood
Observed names:
C. Arrowood,
Christy A. Arrowood
Observed institutions:
West Virginia University,
Duke University,
University of Chicago,
Duke Medical Center,
Rocky Mountain Cancer Centers,
Duke Cancer Institute
show all 6
ORCID:
0009-0000-3263-9659
Observed ORCID:
0009-0000-3263-9659
OpenAlex ID:
A5113878292
Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma
2021
·
Cara Kenney
, Tricia Kunst
, et al.
·
Investigational New Drugs
·
47
PDF
Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors
2006
·
Y. Zafar
, J. Bendell
, et al.
·
Journal of Clinical Oncology
·
33
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer
2013
·
John H. Strickler
, Shannon McCall
, et al.
·
Investigational New Drugs
·
27
Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study
2014
·
Kellen L. Meadows
, Christel Rushing
, et al.
·
Supportive Care in Cancer
·
24
A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)
2019
·
Jeffrey Melson Clarke
, Gerard C. Blobe
, et al.
·
Cancer Chemotherapy and Pharmacology
·
18
PDF
A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer
2019
·
John H. Strickler
, Christel N. Rushing
, et al.
·
BMC Cancer
·
10
PDF
Results of a phase I study of bevacizumab (BV), everolimus (EV), and erlotinib (E) in patients with advanced solid tumors
2007
·
J. C. Bendell
, D. George
, et al.
·
Journal of Clinical Oncology
·
10
A phase 1 first-in-human study of interferon beta (IFNβ) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non–small-cell lung cancer (NSCLC).
2023
·
Andreas Nicholas Saltos
, Christy Arrowood
, et al.
·
Journal of Clinical Oncology
·
8
PDF
BACCI: A phase II randomized, double-blind, placebo-controlled study of capecitabine bevacizumab plus atezolizumab versus capecitabine bevacizumab plus placebo in patients with refractory metastatic colorectal cancer.
2018
·
Niharika B. Mettu
, Donna Niedzwiecki
, et al.
·
Journal of Clinical Oncology
·
8
Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
2011
·
J. H. Strickler
, A. L. Cohn
, et al.
·
Journal of Clinical Oncology
·
5
Abstract CT103: A phase 1 first-in-human study of MEM-288 oncolytic virus in solid tumors including non-small cell lung cancer (NSCLC): impact on tumor and systemic T cell immunity
2023
·
Andreas N. Saltos
, Christy Arrowood
, et al.
·
Cancer Research
·
4
Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).
2016
·
John H. Strickler
, Christel N. Rushing
, et al.
·
Journal of Clinical Oncology
·
4
A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with MET amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA.
2020
·
Jingquan Jia
, Donna Niedzwiecki
, et al.
·
Journal of Clinical Oncology
·
3
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
2012
·
Fatima A. Rangwala
, Johanna C. Bendell
, et al.
·
Journal of Clinical Oncology
·
3
Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
2011
·
A. Starodub
, A. L. Cohn
, et al.
·
Journal of Clinical Oncology
·
3
Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL).
2016
·
Jeffrey Melson Clarke
, Gerard C. Blobe
, et al.
·
Journal of Clinical Oncology
·
2
Topical sildenafil in the treatment of hand-foot syndrome and hand-foot skin reaction: A retrospective study.
2018
·
Christy Arrowood
, Christel N. Rushing
, et al.
·
Journal of Clinical Oncology
·
1
X-TRAP: Phase I/II study of capecitabine (X) plus ziv-aflibercept (TRAP) in metastatic colorectal cancer (mCRC).
2016
·
John H. Strickler
, Fatima A. Rangwala
, et al.
·
Journal of Clinical Oncology
·
1
Supplementary Table S4 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
2025
·
Yingmiao Liu
, Jiatong Li
, et al.
Supplementary Figure S3 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
2025
·
Yingmiao Liu
, Jiatong Li
, et al.
Supplementary Table S1 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
2025
·
Yingmiao Liu
, Jiatong Li
, et al.
Supplementary Table S5 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
2025
·
Yingmiao Liu
, Jiatong Li
, et al.
Supplementary Figure S2 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
2025
·
Yingmiao Liu
, Jiatong Li
, et al.
Supplementary Figure S1 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
2025
·
Yingmiao Liu
, Jiatong Li
, et al.
Supplementary Table S3 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
2025
·
Yingmiao Liu
, Jiatong Li
, et al.
Show more works
View as search
Works count:
34
Citation count:
211
H-index:
8
I10-index:
7
Year
Topic
Type
